Stay updated on Pembrolizumab for Genomic Instability Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page
- Check6 days agoChange DetectedRemoved the 'Last known status' section and the entry for Eugenia Girda, MD, Rutgers Cancer Institute of New Jersey.SummaryDifference0.4%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page header/footer now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0. This is a minor version change that does not affect the trial information or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a 'Results Submitted' status to the study page, replacing the previous 'No Results Posted' notice. This indicates that trial results have been submitted and are now available for review.SummaryDifference0.4%

- Check42 days agoChange DetectedThe updates appear to be formatting adjustments and minor text edits without altering core study details such as eligibility criteria or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check78 days agoChange DetectedUpdated page now shows Revision v3.1.0 and new contact emails/phones; older ovarian cancer-related resources and an older revision v3.0.2 were removed.SummaryDifference0.9%

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.